FINWIRES · TerminalLIVE
FINWIRES

HKG:0460

7 stories mentioning HKG:0460Updated 3d ago

Every FINWIRES story that references HKG:0460, newest first.

Asia

Sihuan Pharmaceutical Expects H1 Profit to Soar At Least 217%

Sihuan Pharmaceutical Holdings Group (HKG:0460) expects to report net profit of at least 210 million yuan for the first half of 2026, up at least 217% from a year earlier.Revenue is expected to be at least 1.14 billion yuan, roughly unchanged from a year earlier, according to a Tuesday Hong Kong bourse filing.The company attributed the expected profit growth to steady development of its medical aesthetics business, continued commercialization of its innovative drug portfolio, and a significant increase in its share of profit from an associate.Shares of the pharmaceutical company rose over 1% in recent trade.

HKG:0460
Asia

Update: Xuanzhu Biopharmaceutical's Reflux Esophagitis Drug Application Accepted in China

(Updating to add stock code of unit and unit's name in headline)Sihuan Pharmaceutical (HKG:0460) unit Xuanzhu Biopharmaceutical's (HKG:2575) new drug application for a new indication of Anaprazole Sodium Enteric-coated Tablets was accepted by China's National Medical Products Administration.The acceptance is for the drug to treat adult reflux esophagitis, according to two Tuesday Hong Kong bourse filings by the companies.

HKG:0460HKG:2575
Asia

Sihuan Pharmaceutical Unit's Reflux Esophagitis Drug Application Accepted in China

Sihuan Pharmaceutical's (HKG:0460) new drug application for the new indication of Anaprazole Sodium Enteric-coated Tablets was accepted by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.The acceptance is for the drug, developed by Xuanzhu Biopharmaceutical, a unit of the company, to treat adult reflux esophagitis.

HKG:0460
Asia

Sihuan Pharmaceutical Trustee Buys Back 8 Million Shares Under Incentive Plan; Stock Slides 4%

Sihuan Pharmaceutical's (HKG:0460) trustee bought back 8 million shares of the firm from the market for around HK$1.0052 apiece under a 2022 share award scheme, according to a Wednesday filing with the Hong Kong bourse.The company's shares fell nearly 4% in late morning trade Thursday.The shares represent 0.0877% of the pharma firm's issued share capital.

HKG:0460
Asia

Sihuan Pharmaceutical's Trustee Buys Back Shares Under Award Scheme

Sihuan Pharmaceutical's (HKG:0460) trustee bought back 3 million shares of the firm from the market for around HK$1.3567 apiece under a 2022 share award scheme, according to a Tuesday filing with the Hong Kong bourse.The shares represent 0.0328% of the pharma firm's issued share capital.

HKG:0460
Asia

Xuanzhu Biopharm Cancer Drug Found to Benefit Patients in Study

Sihuan Pharmaceutical Holdings Group (HKG:0460) said a drug developed by its non wholly-owned subsidiary Xuanzhu Biopharmaceutical (HKG:2575) was found to benefit patients with lung cancer in a late-stage study, according to a Hong Kong bourse filing Monday.Results from the phase 3 clinical trial showed that dirozalkib demonstrated "statistically and clinically significant efficacy advantages" in the first-line treatment of ALK-positive advanced non-small cell lung cancer.In the modified intention-to-treat population, the drug was found to have achieved a median progression-free survival of 31.3 months compared with 12.9 months in the control group.The drug's objective response rate stood at 88.5% with a median duration of response of 32.10 months and a disease control rate of 95.4%.The firm presented the trial results at the 2026 American Association for Cancer Research annual meeting.

HKG:0460HKG:2575
Asia

Xuanzhu Biopharm Gets China Approval to Start Phase 3 Helicobacter Pylori Drug Trial

Xuanzhu Biopharmaceutical (HKG:2575) received approval in China to initiate a phase 3 clinical trial of anaprazole sodium, according to a Wednesday Hong Kong bourse filing by parent Sihuan Pharmaceutical (HKG:0460).The trial will evaluate the drug as part of a bismuth-containing quadruple therapy for the eradication of Helicobacter pylori infection, and plans to enroll 556 adult patients.

HKG:0460HKG:2575

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:0460 in your portfolio
WheelAI
WheelAI
Analyze HKG:0460 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:0460